Law and Regulations

Researchers of a new paper discuss the inconsistencies between gene and cell therapy indications and payor coverage.

The Protect Patient Access to Pharmacies Act will help to secure Medicare patients’ freedom to receive medications and care from the pharmacy of their choice.

According to a spokesperson, the company is prepared to take the lawsuit to the Supreme Court.

Members of the United States Senate Committee on Finance want to modernize the rules around PBM business practices to lower out-of-pocket costs and increase competition.

At the 2023 Asembia Specialty Pharmacy Summit, panelists discussed how inflation rebates and a redesign of Medicare Part D plans will impact payers and manufacturers.

Stipulations of the settlements include data reporting, annual training, and an independent compliance officer.

The DEA is hoping to expand health care accessibility while also safeguarding from incorrectly prescribing medication.

United States leaders work together to create bipartisan solutions for the youth mental health crisis.

At the upcoming hearing, the committee will examine the impact of PBMs on access to healthcare and the Pharmacy Benefit Manager Transparency Act which was submitted by Sens. Maria Cantwell and Chuck Grassley.

President Biden's 2023 State of the Union address highlighted some key areas of health care in which he hopes to make progress.

As President Biden announces the end of the COVID-19 public health emergency, urgency grows.

Experts say Democrats and Republicans could work together on a variety of policy issues over the course of the year.

Experts say Democrats and Republicans could work together on telehealth, mental health and physician payment issues in 2023.

Independent pharmacists stand to gain—or lose—depending on what happens at the polls in November 2022.

No federal agency has taken charge of regulating cannabidiol products, leaving decisions up to the individual states.

Are prescription cap laws for opioids effective for children and teenagers?

Continued advocacy work is the key to seeing state and federal legislative action come to fruition.

Although one in 12 controlled substances medication transactions at US hospitals involve suspicious variations, only about half of such transactions are ever investigated.

Ruxolitinib (Opzelura) cream is the first and only FDA-approved treatment for patients with vitiligo.

According to the agency, this new authority may improve access to patients at high risk for severe COVID-19.

Ruling comes in cases with prison sentences for convictions over prescription drugs.

The bill allows state attorneys general and the Federal Trade Commission the ability to initiate legal action against certain PBM business practices.